Novo Nordisk, once the undisputed leader in the weight loss drug market with Ozempic and Wegovy, is now facing intense competition from Eli Lilly’s Zepbound, which has surpassed it in both efficacy and market share. CEO Maziar Doustdar acknowledges the company’s early missteps in understa
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
Maziar Doustdar
interview on The Journal.
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from The Journal.
The Flu Shot Drama at the FDA
The Vape Cloud Hanging Over the FDA
For Riz Ahmed, Life is a Spy Thriller
How IKEA Is Keeping Its Furniture Affordable
Inside Meta’s Big AI Pivot
Why Hollywood Can't Find Good Scripts
Related episodes
From other shows on similar topics.
Ozempic for All?
The Daily
What we got wrong about GLP-1s
Search Engine
Phil Vella: Ozempic: Life-Saving Drug or Dangerous Shortcut? | DSH #1820
Digital Social Hour
#374 - "Doctors Are Legally BANNED From Telling You This" - Pharma Whistleblower | Brigham Buhler
Danny Jones Podcast
The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You! - Dr. Alex Tatem
The Diary Of A CEO with Steven Bartlett
664. Are Thousands of Medical Cures Hiding in Plain Sight?
Freakonomics Radio
Get summaries like this every morning.
Free AI-powered recaps of The Journal. and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.